169 related articles for article (PubMed ID: 9331891)
1. p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas.
van Haselen CW; Vermeer MH; Toonstra J; van der Putte SC; Mulder PG; van Vloten WA; Willemze R
J Cutan Pathol; 1997 Sep; 24(8):462-7. PubMed ID: 9331891
[TBL] [Abstract][Full Text] [Related]
2. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior.
Vermeer MH; van Doorn R; Dukers D; Bekkenk MW; Meijer CJ; Willemze R
J Clin Oncol; 2001 Dec; 19(23):4322-9. PubMed ID: 11731515
[TBL] [Abstract][Full Text] [Related]
3. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases.
Vergier B; Beylot-Barry M; Pulford K; Michel P; Bosq J; de Muret A; Beylot C; Delaunay MM; Avril MF; Dalac S; Bodemer C; Joly P; Groppi A; de Mascarel A; Bagot M; Mason DY; Wechsler J; Merlio JP
Am J Surg Pathol; 1998 Oct; 22(10):1192-202. PubMed ID: 9777981
[TBL] [Abstract][Full Text] [Related]
4. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance related proteins in primary cutaneous lymphomas.
van Haselen CW; Flens MJ; Scheper RJ; van der Valk P; Scheffer GL; Toonstra J; van Vloten WA
Adv Exp Med Biol; 1999; 457():119-31. PubMed ID: 10500787
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
7. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
[TBL] [Abstract][Full Text] [Related]
8. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins.
Boulland ML; Wechsler J; Bagot M; Pulford K; Kanavaros P; Gaulard P
Histopathology; 2000 Feb; 36(2):136-44. PubMed ID: 10672058
[TBL] [Abstract][Full Text] [Related]
9. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.
Raghavan SS; Hong EK; Kim YH; Kim J
J Cutan Pathol; 2019 Jan; 46(1):33-43. PubMed ID: 30328119
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily.
Paulli M; Berti E; Boveri E; Kindl S; Bonoldi E; Gambini C; Rosso R; Borroni G; Straccapansa V; Magrini U; DeCoteau JE; Krammer PH; Möller P; Kadin ME
Hum Pathol; 1998 Nov; 29(11):1223-30. PubMed ID: 9824099
[TBL] [Abstract][Full Text] [Related]
11. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
[TBL] [Abstract][Full Text] [Related]
12. p53 immunoreactivity is uncommon in primary cutaneous lymphoma.
McGregor JM; Dublin EA; Levison DA; MacDonald DM; Smith NP; Whittaker S
Br J Dermatol; 1995 Mar; 132(3):353-8. PubMed ID: 7718450
[TBL] [Abstract][Full Text] [Related]
13. A review of CD30 expression in cutaneous neoplasms.
Kampa F; Mitteldorf C
J Cutan Pathol; 2021 Apr; 48(4):495-510. PubMed ID: 33047376
[TBL] [Abstract][Full Text] [Related]
14. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas.
Mao X; Orchard G; Russell-Jones R; Whittaker S
Br J Dermatol; 2007 Nov; 157(5):914-21. PubMed ID: 17725669
[TBL] [Abstract][Full Text] [Related]
15. Infrequent expression of protein p53 in epidermotropic variants of cutaneous T-cell lymphoma.
de Misa RF; Azaña JM; Harto A; Bellas C; Ledo A
J Dermatol; 1995 Jul; 22(7):524-6. PubMed ID: 7560447
[TBL] [Abstract][Full Text] [Related]
16. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
18. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins.
Takano Y; Saegusa M; Ikenaga M; Okayasu I
Pathol Int; 1997; 47(2-3):90-4. PubMed ID: 9088026
[TBL] [Abstract][Full Text] [Related]
20. p53 protein expression in cutaneous T-cell lymphomas.
Lauritzen AF; Vejlsgaard GL; Hou-Jensen K; Ralfkiaer E
Br J Dermatol; 1995 Jul; 133(1):32-6. PubMed ID: 7669637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
